FDA Drug Recalls

Recalls / Class II

Class IID-0884-2022

Product

Trulicity (dulaglutide) injection, 0.75 mg/0.5mL once weekly, 4 Single-Dose Pens, Rx only, Eli Lilly and Company, Indianapolis, IN 46285, NDC 0002-1433-80

Brand name
Trulicity
Generic name
Dulaglutide
Active ingredient
Dulaglutide
Route
Subcutaneous
NDCs
0002-3182, 0002-1433, 0002-1434, 0002-2236
FDA application
BLA125469
Affected lot / code info
Lot #: D484557A, Exp: 10/25/2023.

Why it was recalled

TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions

Recalling firm

Firm
Cardinal Health Inc.
Manufacturer
Eli Lilly and Company
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
7000 Cardinal Pl, N/A, Dublin, Ohio 43017-1091

Distribution

Quantity
1 box
Distribution pattern
NM only

Timeline

Recall initiated
2022-04-05
FDA classified
2022-05-19
Posted by FDA
2022-05-25
Status
Completed

Source: openFDA Drug Enforcement endpoint. Recall record D-0884-2022. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Trulicity · FDA Drug Recalls